Clinical Trial Detail

NCT ID NCT01874353
Title Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Recruitment Active, not recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications

peritoneum cancer

fallopian tube cancer

ovarian cancer

endometrial cancer

Therapies

Olaparib

Age Groups: adult senior

No variant requirements are available.